CEACAM5 and neoplasm: Anti-CEA targeted antibodies have been evaluated predominantly in PDAC-targeted fluorescence imaging and to a lesser extent in PET/CT-imaging, demonstrating tumor identification in both preclinical and clinical settings [66,67,68,69,70,71].